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Abstract 
To complement the existing treatment guidelines for all tumour types, ESMO 
organises consensus conferences to focus on specific issues in each type of tumour. 
The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 
2013 in Lugano. A total of 35 experts met to address several questions on non-small-
cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, 
first-line/second and further lines of treatment in advanced disease, early stage 
disease and locally-advanced disease. For each question, recommendations were 
made including reference to the grade of recommendation and level of evidence. 
This consensus paper focuses on locally-advanced disease. 
 
Key words: Non-small-cell lung cancer, locally-advanced, stage III, 
recommendations, ESMO 
 
Key Message: "To complement the existing treatment guidelines for all tumour types, ESMO 
organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO 
Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts 
met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: 
pathology and molecular biomarkers, first-line/second and further lines of treatment in advanced 
disease, early stage disease and locally-advanced disease. For each question, recommendations were 
made including reference to the grade of recommendation and level of evidence. This consensus 
paper focuses on locally-advanced disease." 
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Methods 
 
A detailed literature review was done by the writing group for this manuscript and 
was extended after sending out the preliminary paper to all other Panel Members 
(see Appendix). All available meta-analysis, randomised phase III trials and phase II 
trials considered by the panel as of key importance were put forward for the scoring 
of the guidelines. The scores for Level of Evidence and Grade of Recommendation 
were proposed and fully consented within the writing committee that met at the 
Consensus Conference in Lugano. In an initial summary discussion meeting at the 
Consensus Conference, these scores were already presented to the full Consensus 
Panel and evaluated and amended whenever necessary. During the final writing 
process, these scores were further consented within the writing group together with 
the full Consensus Panel. Final given Levels of Evidence and Grades of 
Recommendation in this manuscript were consented without significant divergence 
between the different Panel Members if not otherwise openly specified in the text 
(Table 1). Statements without grading were considered standard clinical practice by 
the experts. The methods both for the conference and the writing process for this 
topic were as those for the other three manuscripts produced from this conference [1, 
2, 3]. In order to minimise potential bias from the Consensus Panel and writing group, 
the full multidiscplinary manuscript input came from medical oncologists, radiation 
oncologists, thoracic surgeons, pulmonologists and also from pathologists and 
molecular pathologists.  
 
This manuscript covers locally-advanced disease defined as stage III disease 
determined at initial staging, as well as stage III disease found as pathological stage 
III following upfront surgical resection treatment. Table 2 shows the different patient 
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subsets of stage III NSCLC. The Robinson Classification that includes subsets of 
patients that are found only to be pathologically within stage III disease (IIIA1 and 
IIIA2) is mentioned here and later in the text for historical reasons (see also Table 2). 
Some centres still classify patients within stage IIIA(N2) based on these criteria 
although, generally, this classification has lost some of its importance in guiding 
treatment algorithms for individual treatment decisions.  
 
Introduction 
 
Heterogeneity in disease 
 
Locally-advanced NSCLC in this manuscript is defined as stage III NSCLC patients 
according to the most recent (7th) edition of the International Association for the 
Study of Lung Cancer (IASLC)/ Union for International Cancer Control (UICC) TNM 
staging classification. Stage III NSCLC represents a heterogeneous group of patients 
even in the most recent version of the IASLC/UICC TNM staging system (7th edition) 
4. The treatment of such patients may be a challenge because of their local 
presentation, especially in the case of an advanced primary tumour (T4-situation) 
with local infiltration of vital mediastinal organs or involvement of locoregional 
mediastinal lymph nodes (N2 or N3 nodes) and the risk of metastatic recurrence (see 
Table 2) 4. Consequently, the IIIA subset is still to be differentiated from the IIIB 
subset of NSCLC. Definitive cure rates as well as long-term prognosis differ 
significantly between these two substages (see Table 2) 4.  
Furthermore, most randomised studies were performed in the pre-positron 
emission tomography (PET) scan era. The high rate of undiagnosed distant 
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metastases in these patients has most probably diluted any real effect of local control 
on overall outcome. Thus, the current stage III NSCLC population has changed as 
well as the related treatment 5, 6. These changes also contribute to the difficulty of 
interpreting results. Improved outcomes of stage III patients in current studies 
compared with previous trials may result from stage migration, because of the 
increased use of PET and magnetic resonance imaging (MRI) of the brain. There 
have been improvements in surgery (lung-sparing techniques, minimally-invasive 
surgery, pre- and postoperative care), radiotherapy (e.g. image guidance, adaptive 
and respiratory movement techniques) and adjuvant or neoadjuvant chemotherapy 
has become a standard of care in operable stage III patients 7, 8. Adjuvant 
chemotherapy is defined as postoperative chemotherapy that is aimed at the 
treatment of micrometastases to improve cure rates after curative complete resection 
of the tumour at surgery. Neoadjuvant chemotherapy is defined as preoperative 
chemotherapy given to patients that are planned for a curative resection at surgery 
(again for improving cure rates by the early treatment of micrometastases). The 
technical advances of radiotherapy allow for better integration with chemotherapy or 
surgery 9. 
 
Heterogeneity in tumour histopathology 
 
There are data showing that squamous cell carcinoma patients with stage III disease 
tend to have a somewhat better overall survival (OS) prognosis when treated with 
more aggressive combined-modality protocols. They also show a trend for more local 
and locoregional relapse in comparison with adenocarcinoma and large cell 
carcinoma patients who tend to develop more systemic relapses (especially an 
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exceptionally high cumulative rate of brain relapse) 10, 11. However, up to now, this 
has not led to different management strategies for these different entities.  
 
Heterogeneity in tumour location and extension 
 
Large central infiltrating primary tumours without lymph node metastasis (T4N0) have 
a significantly lower tendency to develop systemic metastatic spread than small 
tumours with extensive mediastinal nodal involvement (e.g. T1N3) [12. These two 
entities are characteristic of the remaining wide spectrum in morphological 
presentation of patients amongst the current stage III disease groups. These 
morphological differences may potentially represent underlying differences in 
individual tumour biology, but the exact cellular mechanisms for this heterogeneity 
are still to be determined. The number of involved lymph node stations and the 
location of the nodes also influence the tumour prognosis 13.  
 
Heterogeneity in individual patient risk profile 
 
Long-term smokers (still representing the majority of lung cancer patients) typically 
harbour significant smoking-induced comorbidities such as reduced pulmonary 
function due to chronic obstructive pulmonary disease (COPD), significant cardiac 
problems related to coronary heart disease and vascular problems due to smoking-
induced arteriosclerosis (peripheral and cerebral extension) 14. Thus, this general 
profile of cardio-pulmonary higher-risk patients may significantly hamper curative-
intent and radical treatment strategies.  
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Inter-institution diversity (technical availability/local expertise/experience)  
 
Stage III disease curative-intent strategies require considerable expertise of the staff 
at the treatment centre. Thoracic surgery for stage III disease may imply extensive 
operations including sleeve resections and resection of locally-invaded mediastinal 
organs (e.g. trachea, vena cava, vertebra, pericardium, parts of the right atrium) 15. 
Expertise in radiation oncology is needed to be able to evaluate toxicity/efficacy ratio, 
specify target volumes, and determine organs at risk and doses that can safely be 
delivered. Expert staff are also needed to proceed with appropriate treatment 
including proper quality assurance, bearing in mind that treatment is a multi-modality 
strategy 9.  
 
In consideration of the guidelines, an individualised decision must be made 
within a multidisciplinary team  
 
With this background of individual risk profiles and different morphological tumour 
presentation on one hand, and different treatment strategies on the other, the patient 
with stage III disease should be discussed by a multidisciplinary team including 
pulmonologists, thoracic/medical oncologists, radiation oncologists and thoracic 
surgeons 16. Closely-integrated radiologists and nuclear medicine physicians for 
clinical imaging of the tumours, and pathologists for primary diagnosis and local 
extension at the time of surgery (frozen sections) must be available at the individual 
institution.  
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Due to the complexity of most stage III disease presentations that require 
multidisciplinary treatment, management should be performed in high volume 
centres 
 
High procedure volume is strongly associated with improved survival after lung 
cancer surgery [17. For other multi-modality treatment strategies (induction 
chemotherapy followed by surgery, definitive chemoradiotherapy) it is at least 
possible that high procedure volume may play a comparably important role. 
Concerning radiotherapy, it has been shown that within clinical trials where quality 
assurance of radiotherapy has been implemented, protocol deviations of 
radiotherapy delivery were associated with increased risks of treatment failure and 
overall mortality 18. Another example is Pancoast tumour resection (sulcus superior 
tumours) after combined chemoradiotherapy; this should preferably be performed in 
centres with specific expertise in the management of Pancoast tumours 19. 
 
Results interpretation limited by conduct of trials in highly selected patient 
subpopulations 
 
While randomised phase III clinical trials in stage IV disease and early disease 
stages I and II can frequently recruit between 400 and 2000 patients, there are 
significantly fewer randomised controlled trials completed in stage III disease 7, 8. 
The majority of randomised trials defining the standards of care in stage III disease 
enrolled between 80 and 500 patients 20, 21, 22, 23. This reflects a significant 
selection bias of patients for inclusion into these randomised trials (in terms of age, 
performance status [PS] and stage), questioning the generalisation of these trial 
results to each individual patient presenting with a stage III NSCLC. If we consider 
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trials that compared sequential versus concomitant chemotherapy and radiotherapy, 
they included few patients older than 70 years of age (only 16%) 24, whereas the 
median age for diagnosis of lung cancer is currently about 72 years of age. 
 The gold standard end point in clinical trials is OS. However, a recent study, 
based on a re-analysis of randomised trials having evaluated radiotherapy and 
chemotherapy contribution in locally-advanced and operable NSCLC patients, 
investigated a possible correlation between OS and surrogate endpoints. It seems to 
show that disease-free survival (DFS) can be a valid surrogate endpoint for OS in 
studies of adjuvant chemotherapy, and progression-free survival (PFS) could be a 
valid surrogate for OS in trials evaluating chemotherapy and radiotherapy in locally-
advanced lung cancers [25]. With lung cancer patients at high risk for comorbidity-
related events, some investigators also think that cancer-specific survival (rarely 
determined, yet included in published clinical trials results) may be a further important 
surrogate endpoint for OS in these stage III disease populations with multiple 
competing underlying risks 26. 
 
Additional staging systems for stage IIIA NSCLC 
 
Surgical resection remains an important part of the multidisciplinary management at 
least for selected stage IIIA(N2) patients. Thus, some centres (although overall in 
decreasing numbers) still stratify patients according to the “Robinson Classification of 
N2-disease” (see also Table 2) 27. This classification – besides the routine TNM 
staging – may further mirror some of the heterogeneities of stage III disease. With 
definitive chemoradiotherapy now being increasingly performed at several thoracic 
institutions, this classification has lost some of its former clinical importance to guide 
treatment algorithms, but is mentioned here for historical reasons. 
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The ESMO 2013 Clinical Practice Guidelines [16] presented a more practical 
scheme, integrating CT-scan findings, the application of invasive staging, the 
categories of N2 disease, and the ensuing treatment strategy (Figure 1). This 
approach is further detailed in sections 4.1 and 4.2 of this document. 
 
1. How do we substage stage III NSCLC for decision-
making? 
 
In the rare cases when stage III disease patients undergo primary surgical 
resection, there is a proposed definition of a surgically complete resection. In 
the majority of patients where stage III disease is confirmed by initial staging 
investigations, it is still of importance to classify them at baseline as 
resectable (1), potentially resectable with an increased risk for incomplete 
resection (2) or unresectable (3). 
 
In the rare cases where patients are initially taken to surgery and are resected and 
found to have stage III NSCLC, complete resection is pathologically defined by the 
confirmation of negative surgical margins in the resected specimen, including highest 
mediastinal node negativity at the time of resecting surgery and/or mediastinal lymph 
node dissection 28.  Difficulty in assessing extracapsular lymph node extension 
upfront has a comparable impact on positive resection margins 13, 29, 30. The 
majority of patients in stage III, however, will be found to have stage defining 
extension (e.g. T,N) in the initial imaging and invasive staging investigations. Since 
the possibility of complete resection is an outcome parameter with major impact on 
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the overall prognosis of the patient, the multidisciplinary panel including radiologists, 
pulmonologists and thoracic surgeons should classify the patient upfront as either 
clearly potentially resectable (1), potentially resectable as part of an intermediate 
group (2) or definitely unresectable (3). In the intermediate group, resection is 
deemed to have an underlying increased risk of an incomplete resection. Here, 
typically tumours of the superior sulcus (Pancoast) and specific centrally-located 
tumours (T3/T4-involvement) can be identified 12, 31. Evaluating and predicting 
these parameters upfront is key for adequate planning of the definitive local 
treatment without treatment interruptions (either surgery, a neo-adjuvant 
chemotherapy or chemoradiotherapy approach, as defined by an initial combination 
chemotherapy given prior to any definitive local therapy such as surgery or primary 
definitive radiation/chemoradiotherapy), because of its complexity and the risk that a 
wrong decision may result in an unsuccessful outcome. This could lead to palliative 
treatment (e.g. an incomplete resection after preoperative concurrent chemotherapy 
and radiotherapy to a dose of 45 Gy).  
 
2. What is the optimal diagnostic work-up for stage III 
NSCLC patients? 
 
2.1. Positron emission tomography-computed tomography (PET-CT)  
 
All patients planned for definitive stage III NSCLC treatment should undergo a 
diagnostic high-resolution CT followed by a PET or a combined PET-CT with a 
CT technique with adequately high resolution for initial staging purposes [I, A] 
in order to rule out detectable extrathoracic extracranial metastasis and to 
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assess potential mediastinal lymph node involvement, ideally within 4 weeks 
before the start of treatment [III, B]. Single PET-positive distant lesions need 
pathological confirmation [V, B]. 
 
Several randomised trials have investigated the diagnostic impact of whole body 
PET-CT for initial staging of stage III NSCLC patients 32, 33, 34, 35, 36. This 
investigation may rule out extracerebral metastases prior to decision-making for any 
local treatment with a curative intent. Mediastinal lymph node staging may be 
initiated by this method 33. Further pathological confirmation of suspected lymph 
node stations should follow using endoscopic bronchial ultrasound (EBUS), 
endoscopic ultrasound (EUS), cervical mediastinoscopy or VATS (video-assisted 
thoracoscopy) investigations including VAMS (video-assisted mediastinoscopy) or 
VAMLA (video-assisted mediastinal lymphadenectomy) 37, 38, 39, 40. Single PET-
positive distant lesions need pathological confirmation prior to accepting stage IV 
clinical staging status for any patient 5. The quality of the local CT-component in 
this setting is critical. Only the most modern generation of PET-CT scanners have 
high resolution CT-scanners embedded into the investigation. A high-enough-
resolution CT scan for initial imaging evaluation of the primary tumour and the 
mediastinal organs should not be skipped for a less diagnostically accurate 
conventional CT-scan.  
 
2.2. (Minimally-)invasive mediastinal staging (1) (transbronchial needle 
aspiration[TBNA]/EBUS/EUS/mediastinoscopy)  
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PET-positive mediastinal findings should be pathologically assessed [I, A]. 
Invasive mediastinal staging may still be indicated despite PET negativity in 
case of suspicious lesions (primary tumour of >3 cm large axis, central 
tumours, cN1, CT-enlarged lymph nodes with small axis >1 cm) [III, B].  
 
Endoscopic methods should be preferred as the initial interventional 
procedure whenever feasible [I, A]. In case of negative endoscopic findings, 
and high suspicion of mediastinal node involvement, surgical staging is 
indicated [I, A]. 
 
PET-positive mediastinal findings should always be confirmed cytologically or 
histologically, preferably at first by minimally invasive mediastinal staging. Methods 
available include TBNA, guided by EBUS or oesophageal EUS 34, 37, 38, 39, 40. 
PET-CT has a high negative predictive value but its positive predictive value is not so 
widely accepted 36, 37]. Therefore, if significant impact on the overall treatment 
strategy is assumed, which is the case with most stage III NSCLC, PET-positive 
mediastinal findings should be pathologically assessed. If mediastinal nodes are 
PET-negative but suspicion of tumour involvement remains (criteria: primary tumour 
of ≥ 3 cm large axis, central tumours, cN1, CT-enlarged lymph nodes with their small 
axis  ≥ 1 cm), there may still be an indication for minimally invasive mediastinal 
staging investigations in the form outlined above 36, 37]. 
Following PET-CT investigations, endoscopic methods represent the easiest 
interventional procedure 36. If the results of these diagnostic procedures are 
negative despite a high suspicion of mediastinal node involvement, surgical staging 
of the mediastinum is clearly indicated 34. If surgical staging of the mediastinum is 
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indicated, VAMS is the preferred technique for upper mediastinal lymph nodes and 
VATS is preferred for aorto-pulmonary lymph nodes 34.  
 
 
2.2. Brain magnetic resonance imaging (MRI) / Brain computed tomography 
(CT) 
 
All patients planned for curative stage III NSCLC treatment should receive 
brain imaging for initial staging [III, B]. Contrast-enhanced brain MRI is the 
preferred method for staging of the brain in stage III disease [III, A]. 
Alternatively, dedicated contrast-enhanced brain CT can be performed [III, B]. 
 
Patients with locally invading T4-tumours and N2- or N3-mediastinal nodal 
involvement have an underlying high risk of primary brain metastases 41, 42. 
Therefore, if curative definitive treatments are planned for these patients, initial 
staging of the brain with adequate imaging methods should generally be performed 
43. The method of choice is contrast-enhanced brain MRI. Contrast-enhanced brain 
CT can be performed as a valid alternative in case of contraindications to MRI or 
unavailability. Some studies have shown an adequate positive predictive value for 
this method but its quality may vary from centre to centre and needs further critical 
evaluation 44.  
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3. What are the most relevant comorbidities assessed in 
the clinical work-up of stage III NSCLC patients? 
 
3.1. Cardio-pulmonary functions are relevant for multidisciplinary treatment 
decisions including surgery [II, A] or radiotherapy [III, C].  
 
Patients for whom a surgical intervention is planned must be functionally assessed 
for surgery. This includes adequate cardio-pulmonary function testing. Guidelines for 
these evaluations have been published by the European Respiratory Society (ERS) 
14. Cardiac function may be investigated by electrocardiogram (ECG), 
echocardiography, stress ECG, stress-echocardiography or even coronary 
angiography including left ventricular catheterisation, in selected cases 14. 
Pulmonary function testing includes spirometry and diffusion capacity of the lung for 
carbon monoxide, split function studies (especially perfusion scintigraphy) and 
exercise tests (in particular, peak oxygen consumption) 14. With a specific lung 
resection planned at surgery, lung function parameters can be predicted for the 
postoperative setting following assumed lobectomy as well as pneumonectomy 14. 
These parameters have been standardised and are important in evaluating patients 
fit for radical (curative) surgical treatment. The ERS consensus group has also made 
some proposals for patients planned for curative radiotherapy and 
chemoradiotherapy approaches 14. Unfortunately, currently post-radiotherapy lung 
function cannot be readily predicted taking into account the planned treatment 
volumes. There is indeed a lack of data on the influence, if any, of pulmonary 
function tests on radiation-induced lung toxicity, the interplay between pre-existing 
comorbidities and systemic treatments and possible adverse effects 9. More 
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prospective data are warranted on the toxicity and outcome of chemoradiotherapy. 
Many studies, mostly retrospective, have addressed the relationship between dose 
and volume to organs at risk, such as normal lung, heart, oesophagus and spinal 
cord, in predicting the probability of radiation-induced damage. Some of these 
studies have included patient factors 45, 46. In conformal radiotherapy, dose 
volume histograms (DVH) to the tumour and nodal volume, as well as organs at risk, 
contribute to determining the optimal treatment plan for each individual patient. Dose 
constraints have thereby been defined according to DVH parameters and several 
normal tissue complication probability models in the clinic, and are also being used in 
prospective studies 46, 47. No robust data are, however, currently available linking 
DVH data to heart toxicity. 
 
3.2. Comorbidities are of paramount importance since the potential risk of 
toxicity/morbidity/mortality has to be balanced with the potential benefit of any 
aggressive curative-intent treatment strategy [III, A]. 
 
The comorbidity profile of the patients has to be critically analysed prior to any 
curative-intent treatment decision in stage III disease 48, 49. This includes definitive 
surgery on one hand, but also definitive chemoradiotherapy on the other. Significant 
toxicities during aggressive treatment can be observed following a history of recent 
vascular events of the patient, such as myocardial infarction or stroke (e.g. within the 
last six months prior to treatment). Further significant comorbidities are represented 
by renal insufficiency or necessary haemodialysis that may create difficulties at the 
time of chemotherapy or surgery. Heart failure and cardiac rhythm disorders must be 
critically acknowledged – as well as diabetes mellitus, which must be treated 
adequately prior to any local treatment. Frequently used scores include the Charlson 
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Comorbidity Index (CCI) in either the full or an abridged, simplified version 49, 50. 
However, the ERS recommends the use of the full version of the CCI for better 
comparability of the datasets. Evaluation of comorbidities is included in a 
comprehensive geriatric assessment for elderly patients 48. Insufficient prospective 
evidence has been generated to reliably disqualify a patient from radical treatment 
based on one of these scores, and further prospective studies are urgently needed.  
3.3. For curative-intent management, patients should be able to undergo 
platinum-based chemotherapy (preferably cisplatin) [I, A]. 
 
Both for (neo-)adjuvant chemotherapy coupled with complete resection in stage IIIA 
disease as well as for concurrent or sequential chemoradiotherapy protocols in stage 
III disease, the patients should be able to undergo platinum-based chemotherapy 7, 
8, 23. Concurrent chemoradiotherapy is defined as simultaneous (“same-day”) 
administration of an active chemotherapy in parallel to ongoing thoracic radiotherapy 
fractions. Sequential chemoradiotherapy is defined as giving upfront combination 
chemotherapy for several cycles followed by a block of fractionated radiotherapy only 
(for five to seven weeks). The clearest evidence exists for cisplatin-based doublets 
(cisplatin and etoposide or cisplatin and vinorelbine or other vinca alkaloids). This 
has been sufficiently demonstrated by the Lung Adjuvant Cisplatin Evaluation (LACE) 
meta-analysis 7. Cisplatin can be easily administered to the majority of patients 
excluding only those few with significant renal failure or heart failure 51, 52. 
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4. What are the optimal multimodality combinations for the 
different stage III disease substages? 
 
4.1. Incidental IIIA(N2) (unforeseen N2) (Table 2, Figure 1) 
 
If, despite adequate mediastinal staging procedures, N2 disease is only 
documented intraoperatively, surgery should be followed by adjuvant 
chemotherapy [I, A]. In case of complete resection, addition of postoperative 
radiotherapy is not routinely recommended, but may be an option following 
individual risk assessment [V, C].  
 
Patients that were classified as having stage I or stage II disease in the staging 
investigations but are found to have an incidental intraoperative N2 diagnosis (“old 
classification”: macroscopic N2-involvement Robinson IIIA1 and microscopic N2-
involvement IIIA2) have a relatively good prognosis and must be considered for 
adjuvant chemotherapy (Table 2) 7. Adjuvant chemotherapy is defined as 
chemotherapy, given after the complete resection of a resectable tumour, to reduce 
relapse based on micrometastases. These patients typically cannot be identified 
upfront and preoperatively as having stage III disease. There is an ongoing 
discussion about adjuvant postoperative radiotherapy for these patients and, 
therefore, an ongoing European trial (LungART) is evaluating this strategy 53. 
Retrospective analysis from randomised trials and from a SEER database analysis 
suggest a potential benefit of adjuvant radiotherapy in N2 disease 54, 55, 56. Even 
though it is unclear whether modern adjuvant postoperative radiotherapy may have 
an impact on the outcome of such patients, if the individual assessment of loco-
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regional risks shows a high probability of local failure, postoperative radiotherapy 
may be a valid option. It should then be delivered after adjuvant chemotherapy, as 
concurrent post-operative chemoradiotherapy is not routinely recommended 57. 
Patients who have been incompletely resected with an R1 (microscopic) or R2 
(macroscopic) resection specimen result should be discussed individually in the 
multidisciplinary panel. Postoperative thoracic radiotherapy or even, in rare cases, 
concurrent chemoradiotherapy protocols may be an option for some of these patients 
but no clear guideline currently exists since the number of these patients is extremely 
small. For decision-making, it is probably best to weigh the risks of locoregional 
relapse against the risk of systemic relapse in the individual patient. With better and 
more critical selection for stage III disease patients to undergo surgical measures the 
percentage of incomplete resections can be kept sufficiently low.    
 
4.2. Potentially resectable IIIA(N2) disease (Table 2, Figure 1) 
 
4.2.1. Preoperative diagnosis of IIIA(N2) 
 
Possible strategies include several options: induction chemotherapy followed 
by surgery, induction chemoradiotherapy followed by surgery, or concurrent 
definitive chemoradiotherapy [I, A]. No recommendation can yet be made; 
however, an experienced multidisciplinary team is of paramount importance in 
any complex multimodality treatment strategy decision. If induction 
chemotherapy alone is given preoperatively, postoperative radiotherapy is not 
standard treatment but may be an option based on critical evaluation of loco-
regional relapse risks [IV, C]. 
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In patients with preoperatively confirmed IIIA(N2) disease based on the performed 
staging investigations, different multimodality treatment strategies can be envisaged, 
including induction chemotherapy followed by surgery 21, 58, 59, 60, 61, 62, 63, 
induction chemoradiotherapy followed by surgery, or definitive chemoradiotherapy 
protocols 23, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73. Only full-dose, definitive 
concurrent chemoradiotherapy vs. induction concurrent chemotherapy and 
radiotherapy followed by surgery has been investigated in a prospective randomised 
North American Intergroup trial, in which patients had have histo- or cytologically 
proven N2-disease and for whom definitive chemoradiotherapy was to be considered 
the standard approach (comparator arm of this study) [22]. Patient selection for this 
multicentre randomised trial included patients that were evaluated to be potentially 
resectable with stage IIIA(N2) disease. No difference in OS by intent to treat analysis 
but a better PFS for patients with surgery was observed 22. It is the general 
perception that both treatment strategies remain possible options in this situation 
based on the final results of this clinical trial. However, toxicity of surgery in the local 
treatment centre setting remains a significant issue. In the Intergroup study, 54 of the 
155 resections were pneumonectomies; 14 patients treated with pneumonectomy 
died within 30 days after surgery. An observed 26% mortality rate in the right-sided 
pneumonectomy patients is significantly higher than what is generally considered 
acceptable for this procedure and, also, has not been seen and reported by 
experienced thoracic centres in Europe, North America and Asia. A recent analysis, 
systematic review and meta-analysis of perioperative mortality after neoadjuvant 
therapy and pneumonectomy for NSCLC revealed an overall 30-day mortality of 7% 
among the 27 published studies included in the review which is significantly less 
reported toxicity than in the multi-centre North American study – predominantly after 
pneumonectomy [74, 75, 76, 77].  
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Other centres have performed large trials with induction chemotherapy 
followed by surgery, or by definitive chemoradiotherapy without surgery, with more or 
less comparable OS data 20, 21, 23, 59, 60, 61, 62, 63, 64.  
The EORTC study also required upfront cytological or histopathological proof 
of N2-disease in a group of patients defined as unresectable per protocol [21]. 
Patients received three cycles of induction chemotherapy treatment – eighteen 
different chemotherapy protocols were included – and those who showed any 
response (complete, partial or minor) to induction were randomised either to surgical 
resection or definitive radiotherapy. Patients included into this trial were most likely in 
advanced IIIA(N2) disease as only 50% of the patients could be randomised 
following induction [21]. No difference was noted between the two randomisation 
arms in either OS data of both arms or PFS results. The patient population of this 
study is probably not directly comparable to the one included into the Intergroup trial, 
which makes combined analysis of these two trials very difficult. The selection 
procedure of the EORTC study with upfront induction chemotherapy was probably 
responsible for the upfront more advanced stage IIIA(N2) population. Another 
criticism of this study is that the comparator arm was radiotherapy alone and not 
concurrent chemoradiotherapy. This, furthermore, makes the final impact of its 
outcome difficult to bring into perspective with the more standard concurrent 
chemoradiotherapy strategies for these patients in the present day.  
A recent study by the Swiss Group (SAKK) was presented at ASCO in 2013 
[78] and at ESMO in 2014 [79]. The study included patients with cytologically- or 
histologically-proven IIIA(N2) disease and randomised to induction chemotherapy 
followed by surgery versus induction chemotherapy followed by radiotherapy and 
then definitive surgery. Both the primary endpoint of the trial (OS) as well as the 
secondary endpoint (PFS) showed no significant differences between the arms. It is 
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noteworthy that the employed induction chemotherapy protocol was cisplatin and 
docetaxel. Since a high percentage of patients could be taken to surgery following 
induction chemotherapy alone, the patient selection of this study included more 
potentially resectable IIIA(N2) disease patients and the induction chemotherapy 
turned out to be quite effective in inducing downsizing and downstaging. 
Based on these different trials results, it is the general perception that, in these 
complex treatment situations, the overall expertise of the multimodality team at the 
treatment centre is probably of more importance for the overall outcome of the 
patient than the exact schedule and permutation of the multimodality treatment 
protocol 16. It should be outlined that such treatment should preferably be decided 
upfront, in the presence of an experienced thoracic surgeon, respecting the delay of 
about four weeks between the end of radiotherapy and surgery and the fact that any 
split in the radiotherapy application has to be avoided, if possible. 
 
4.2.2. Potentially operable IIIA(N2) disease and selected IIIB disease - but at 
high risk of incomplete resection (Table 2, Figure 1) 
 
In potentially resectable superior sulcus tumours concurrent chemo-
radiotherapy induction followed by definitive surgery is the treatment of choice 
[III, A]. The same strategy may be applied for potentially resectable T3 or T4 
central tumours in highly selected cases and experienced centres [III, B]. In 
both situations, surgery should be performed within 4 weeks after the end of 
radiotherapy [III, B]. 
 
For potentially resectable superior sulcus tumours, concurrent chemoradiotherapy 
induction followed by surgery has become the standard of care 80. As randomised 
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trials are difficult to perform because of rarity of these tumours, this recommendation 
is based on a multicentre prospective phase II Southwest Oncology Group (SWOG) 
trial in North America, which demonstrated an excellent complete resection rate and 
markedly improved five-year survival rates 80. A comparable strategy using 
concurrent chemoradiotherapy to downsize the primary tumour and downstage 
centrally-located tumours may be applied to certain T3 N2 or T4 N0-1 tumours 27, 
28, 65, 66, 67, 68. Several groups have reported excellent complete response and 
long-term survival rates following such induction therapy in these IIIA and selected 
IIIB subset 27, 28, 65, 66, 67, 68. Recently a German Group presented a pilot 
phase II trial and a randomised phase III trial looking at surgery versus definitive 
chemoradiotherapy boost following complex induction chemotherapy and concurrent 
chemoradiotherapy (ESPATÜ) 65, 81. No benefit in OS and PFS for surgical 
resection was noted in this trial but both study arms showed excellent long-term 
survival results. The patient subsets of this study included potentially resectable 
IIIA(N2) disease patients and centrally located T4N0-1 both groups with underlying 
risks for incomplete resection. The best results for the patients in this study were 
noted in the T4N0-1 subset (now stage IIIA [IASLC/UICC 7th edition]).  
 
4.3. Unresectable IIIA (N2) disease and IIIB disease patients (Table 2, Figure 1) 
 
Concurrent chemoradiotherapy is the treatment of choice in patients evaluated 
as unresectable in stage IIIA and IIIB [I, A]. If concurrent chemoradiotherapy is 
not possible – for any reason - sequential approaches of induction 
chemotherapy followed by definitive radiotherapy represent a valid and 
effective alternative [I, A]. 
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This group includes both unresectable IIIA(N2) disease based on bulky and multiple 
mediastinal nodal involvement and IIIB disease based on unresectable T4 
involvement or any N3-disease in the mediastinal nodes. For these patient groups 
definitive radiotherapy and chemotherapy combinations remain the treatments of 
choice. Concurrent chemoradiotherapy generally gives significantly better OS results 
than sequential chemotherapy and radiotherapy protocols in unresectable IIIA and 
IIIB disease 20, 21, 22, 23, 82, 83, 84, 85. This is based on several phase III trials 
and a meta-analysis based on individual patient data 24. There was a significant 
benefit of concomitant chemoradiotherapy on OS with an absolute benefit of 4.5% at 
5 years (HR, 0.84; P = 0.004). These trials were performed with presently outdated 
staging methods and mostly 2D radiotherapy techniques.  
 Patients who are considered to be unfit for concurrent chemotherapy and 
radiotherapy can be treated with induction chemotherapy and high-dose radiotherapy 
with curative intent [86, 87, 88, 89]. Accelerated radiotherapy may be beneficial in 
this situation [90, 91, 92] as it has shown superior results [89, 91]. Also, the results of 
an individual-patient-data-based meta-analysis for non-concurrent 
chemoradiotherapy further support this individualised strategy [91]. 
 Few groups have piloted surgery after combined-modality approaches in N3-
disease patients – mostly chemoradiotherapy. There is old phase II data from SWOG 
and from the West German Cancer Centre Group and from several other 
investigations looking at this subset [64, 66, 67, 68]. In the ESPATÜ trial presented at 
ASCO 2014, one third of the patient group included patients with T1-3N3 disease 
with N3 proven and found at staging mediastinoscopy [81]. Long-term survival was 
also noted in both arms of this patient subset. The other groups having explored 
surgical resection for selected N3-patients after induction chemoradiotherapy also 
noted promising results, but this could be related to patient selection and no final 
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evaluation of this treatment strategy can currently be given [64, 65, 66, 67, 68, 81]. 
Concurrent chemoradiotherapy remains the treatment of choice for these patient 
groups outside specific expertise generated by the treatment group or well-designed 
clinical trials. 
 
4.4. Prophylactic cranial irradiation (PCI) 
 
There is currently no role for PCI in stage III NSCLC [II, A]. 
 
Relapse pattern in stage III NSCLC patients has shown a high cumulative risk of 
developing brain metastases 41, 42. Several trials have explored PCI within the 
multimodality strategy. A significant impact on brain relapse as first site of failure and 
on overall-brain relapse rate has clearly been demonstrated 41. However, a recent 
large Radiation Therapy Oncology Group (RTOG) phase III trial addressing the issue 
of PCI in stage III disease patients treated with multimodality therapy was not able to 
demonstrate a significant impact on OS by PCI versus observation 93. This trial 
closed prematurely because of poor accrual; although it was underpowered, it 
showed that PCI could decrease the rate of brain metastases. Other trials are open 
to accrual. 
 
5. What is the optimal chemotherapy to be given to stage III 
disease patients? 
 
5.1. Cisplatin or carboplatin in combination with radiotherapy 
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In the absence of contraindications, the optimal chemotherapy to be combined 
with radiation in stage III NSCLC should be based on cisplatin. There are no 
firm conclusions supporting single-agent carboplatin as a radiation sensitiser 
[I, A]. 
 
For fit patients with inoperable stage III NSCLC, cisplatin-based chemotherapy given 
concurrently to radiation therapy is recommended 23. According to level I evidence-
based medicine, cisplatin may be combined with etoposide, vinorelbine or other vinca 
alkaloids 23,24. However, in some patients, based on specific comorbidities, other 
treatment modalities may alternatively be considered: single-agent cisplatin or 
carboplatin-based chemoradiotherapy, sequential chemotherapy and radiotherapy or 
even radiotherapy alone. These alternatives can be proposed to patients with higher 
risks of infection, general or pulmonary complications. There are already randomised 
clinical trials showing the efficacy of single-agent cisplatin delivered concomitantly 
with radiotherapy 84, 94, 95. On the contrary, single-agent carboplatin has failed to 
improve survival when given concurrently with radiotherapy in two prospective 
randomised trials 95, 96. Recently, an Asian randomised clinical trial comparing 
radiotherapy alone to combination of daily single-agent carboplatin and radiotherapy 
in elderly patients >70 years of age has shown that combined chemoradiotherapy 
could improve outcome in a selected group 97. However, relatively significant 
haematological toxicity was reported. As these data focus on elderly Asian 
populations, some experts think that further safety data should be collected in 
Caucasian patients prior to implementing this approach as a routine schedule, only 
for high-risk patients with significant comorbidities. The major criticism against this 
trial however, is that even in elderly patients, standard treatment should be a 
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platinum-based doublet given concurrent to radiotherapy. Age alone is not an 
argument against a curatively intended protocol.  
 Several North American studies have used the weekly carboplatin and 
paclitaxel regimen concomitantly with radiotherapy with conflicting results. Despite 
this regimen having served as a standard comparator regimen in large clinical trials 
in North America and also in some parts of Europe and Asia, it is not accepted by all 
physicians in these regions 82, 98, 99. Moreover, such a combination remains an 
accepted and valid option for patients who cannot receive cisplatin-based 
chemotherapy because of existing significant comorbidities. If low-dose weekly 
chemotherapy schedules are used in the concurrent treatment phase, it is highly 
recommended to use a full dose platin doublet given either before or after the  
radiotherapy application.  
 
5.2. Chemotherapy combination 
 
Most comparative studies of concurrent chemoradiotherapy versus sequential 
administration were using cisplatin + etoposide or cisplatin + vinca alkaloid 
(typically: cisplatin + vinorelbine). There are no comparative phase III trials 
using the paclitaxel/carboplatin regimen. When delivered perioperatively, 
cisplatin-based combinations are considered the treatment of choice, in the 
absence of contraindications [I, A]. 
Several randomised trials comparing concurrent and sequential chemoradiotherapy 
were included in the individual-patient-data-based meta-analysis 20, 23, 24, 25. 
The North American trial using cisplatin and vinblastine is interpreted as a study 
demonstrating the superiority of the concurrent strategy 23. The small Czech 
randomised study compared the more modern cisplatin and vinorelbine doublet and 
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showed a benefit for the concurrent strategy 84. The West Japan Lung Cancer 
Group (WJLCG) study (although strongly supporting concurrent chemoradiotherapy) 
was based on a mitomycin combination, now rarely used because of potential lung 
toxicity described in earlier observations 20, 75. In the Japanese study, split-dose 
radiation was used – a strategy that would not be supported by modern radiation 
biology considerations 100. The French trial used cisplatin and etoposide and 
favoured the concurrent administration with manageable toxicity 83. The survival 
benefit induced by a platinum-based concomitant strategy has been emphasised in 
an individual-patient-data-based meta-analysis 24, 85. Even if carboplatin-
paclitaxel-based chemoradiotherapy is frequently used, especially in North America, 
it should be underlined that no carboplatin-paclitaxel-based regimen was evaluated in 
any of the individual-patient-data meta-analyses [24]. There is one underpowered 
randomised phase II study that compared a carboplatin and paclitaxel combination 
directly to a cisplatin-based combination, for which the results favoured the cisplatin-
etoposide combination in terms of survival 86. This leads to the consensus that 
cisplatin-based doublets should be preferred in stage III disease multimodality 
protocols when treatment has a curative intent. 
 
5.3. Number of chemotherapy cycles  
 
In the stage III disease chemoradiotherapy strategy, 2-4 cycles of concomitant 
chemotherapy should be delivered [I, A]. There is no evidence for induction or 
consolidation chemotherapy. In the perioperative setting, 3-4 cycles of 
cisplatin-based chemotherapy are recommended [I, A], aiming at a total 
cumulative dose of at least 300mg/m2 of cisplatin in the adjuvant setting [II, B].  
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The majority of randomised clinical trials in stage III NSCLC patients treated by 
concurrent chemoradiotherapy used two to four cycles of cisplatin-based combination 
chemotherapy 24. Based on adjuvant chemotherapy in stage II and stage III 
disease, four cycles of cisplatin-based combination chemotherapy are defined as the 
standard of care 7. In the LACE adjuvant meta-analysis, one of the main prognostic 
factors was the delivery of a cumulative cisplatin dose >300 mg/m2 7. Regarding 
stage III disease chemoradiotherapy, 2-4 cycles of concomitant chemotherapy 
should be delivered [I, A]. There is no evidence for extended induction or 
consolidation beyond these 3 to 4 cycles 98, 99.  
 In operable patients, in the large randomised phase III Intergroup trial 0139, 
the comparative arm used four cycles of cisplatin and etoposide given together with 
thoracic radiotherapy at a dose of 61 Gy. This serves as a landmark study in 
operable stage III(N2) disease 22. In this study, two cycles were given as 
consolidation following the definitive chemoradiotherapy protocol (in 75% of patients).  
 
6. What is the optimal radiation regimen given to stage III 
NSCLC patients? 
 
6.1.1. Dose and fractionation in concurrent chemoradiotherapy 
 
60-66 Gy in 30-33 daily fractions is recommended for concurrent 
chemoradiotherapy [I, A]. Maximum overall treatment time should not exceed 
seven weeks [III, B]. “Biological intensification”, such as treatment 
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acceleration, is not standard practice in concurrent chemoradiotherapy 
schedules [III, B]. 
 
The majority of clinical concurrent chemoradiotherapy regimens in stage III NSCLC 
have used 60-66 Gy cumulative radiotherapy doses in conventional daily fractions of 
1.8-2.0 Gy 23, 83, 84, 85. A detailed look at the relationship of overall treatment 
duration and outcome in these studies has confirmed that prolonged treatment time 
is a critical issue in this setting, as it is in other tumour types 91. The RTOG 0617 
study has confirmed that radiation dose escalation (with conventional 2 Gy per 
fraction regimen leading to a prolonged treatment time exceeding seven weeks) and 
concurrent CT is not the way forward. In this phase 2x2 factorial design phase III 
randomised controlled trial,  patients with stage III NSCLC were randomised to 
receive high-dose (74 Gy in 37 fractions) or standard-dose (60 Gy in 30 fractions) 
radiotherapy concurrently with weekly paclitaxel/carboplatin with or without 
cetuximab [82]. In a planned interim analysis after 90 events, the high-dose arms 
were closed for futility. At a median follow-up time of 22.9 months, survival of 419 
eligible patients was significantly inferior with high-dose compared with standard-
dose radiotherapy; median OS  was 28.7 months (95% CI 24.1-36.9) for patients who 
received standard-dose radiotherapy and 20.3 months (17.7-25.0) for those who 
received high-dose radiotherapy (hazard ratio 1.38, 95% CI 1.09-1.76; p=0.004).. 
However, treatment intensification should not be abandoned in stage III NSCLC. This 
is an area of active research, facilitated by the rapid development of advanced 
radiotherapy techniques. 
6.1.2. Dose and fractionation in sequential chemoradiotherapy 
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Promising outcome is achieved with accelerated radiotherapy [I, A]. A potential 
radiation schedule could be the delivery of 66 Gy in 24 fractions [II, C].  
 
Accelerated radiotherapy has resulted in improved 5-year survival rates compared 
with so-called conventional radiation schedules, i.e. 2 Gy per day five times per week 
52, 89, 91. The CHART regimen serves as a good example that was investigated in 
a large phase III trial in a few stage II disease and mostly stage III disease patients 
and resulted in a significant survival benefit when compared with conventionally 
fractionated treatment application 52. Even today, this treatment protocol is 
selectively used in several European centres, especially in the United Kingdom 
where it was initially piloted. Apart from multiple fractions per day schedules, an 
accelerated high-dose regimen was investigated in one phase II study and one 
phase III study of 66 Gy in 24 daily fractions 89. These specific schedules represent 
valuable alternatives in patients where concurrent chemoradiotherapy protocols may 
not be possible because of comorbidity profile issues and expected toxicities. 
 
6.1.3.   Radiation doses in the preoperative setting 
 
Standard preoperative radiation doses within chemoradiotherapy protocols 
should be between 40 and 50 Gy in conventional fractionation or 40-45 Gy in 
accelerated fractionation (bid application) [I, B]. 
 
The majority of clinical trials that have given preoperative chemoradiotherapy have 
used 40-50 Gy cumulative doses in conventional fractionation of 1.8-2.0 Gy per day. 
Several groups have also employed accelerated hyperfractionation given as 1.5 Gy 
twice daily up to 40-45 Gy. These regimens have been used within larger phase II 
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and randomised multicentre phase-III studies. Furthermore, some investigators have 
piloted higher radiation doses up to 60-63 Gy in conventional fractionation, but this 
has only been done within the phase II setting. As increased preoperative toxicities 
(also described in the literature) may result from these treatment intensifications (e.g. 
radiation pneumonitis, acute respiratory distress syndrome) it is advisable to give 
these higher doses only in the setting of prospective controlled clinical trials. Higher 
preoperative radiation doses may result in higher pathological complete remission 
rates and may potentially optimise preoperative downsizing and down staging but 
these advantages must be carefully weighed against the potentially higher resulting 
toxicities. 
 
6.2. Elective mediastinal nodal irradiation 
 
Elective mediastinal nodal irradiation – prophylactic irradiation of non-involved 
mediastinal nodes – is not recommended [I, B]. 
 
Prophylactic irradiation of non-involved mediastinal nodes is no longer recommended 
when using modern diagnostic and chemoradiotherapy strategies, neither in 
sequential nor in concurrent chemoradiotherapy 101. Microscopic disease at this 
level is assumed to be treated by systemic chemotherapy combined with radiation. 
However, selective nodal irradiation can only be recommended when at least a 
fluorodeoxyglucose (FDG)-PET-CT scan is available and shows signs of loco-
regional extension. Adequate mediastinal staging is, therefore, also recommended in 
non-surgical patients targeted for treatment with curative intent 90]. 
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6.3. Radiotherapy technique 
  
Quality assurance and dose constraints are required as a prerequisite [I, A].  
 
It is recommended that high-dose radiotherapy is prepared and executed according 
to standards such as those of the European Organisation for Research and 
Treatment of Cancer (EORTC) 9. More and more centres use respiration-correlated 
CT scans (or “4D CT”), so as to take into consideration tumour movement in thoracic 
oncology 102, 103. Respiratory gating and tumour movement adaptations, as well 
as intensity modulated radiotherapy (IMRT), are important points for further 
improvement of targeting radiation delivery to the primary tumour and involved nodes 
102, 103. However, these treatment modalities are not yet used at all treatment 
centres. 
 
7. What is the optimal surgical management in resectable 
stage III NSCLC patients? 
 
7.1. Type and extent of surgery 
 
The optimal surgical management aims at complete resection – preserving as 
much non-involved parenchyma as possible, preferably performed by 
lobectomy/sleeve resection [I, A]. Complete resection necessarily includes 
systematic mediastinal nodal exploration. In selected patients, 
pneumonectomy must be performed, but should be adequately selected and 
the procedure restricted to experienced centres [III, B]. 
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Curative surgery in stage III disease will preferably include surgical techniques such 
as lobectomies, bi-lobectomies and sleeve resections, to spare lung tissue as much 
as possible 76. Nevertheless, in recent years, it has become clear that in selected 
patients, complete resection will require a pneumonectomy or, in some cases, a 
sleeve pneumonectomy, which can be safely conducted in experienced high volume 
centres 74, 76, 77. 
 
7.2. Postoperative mortality related to surgical intervention 
 
Based on reported series, post-lobectomy and pneumonectomy mortality rates 
should not exceed 2%-3% and 3%-5%, respectively [IV, B]. 
 
Postoperative mortality resulting from stage III disease surgical resections should be 
evaluated in every thoracic centre. Modern published series show that surgical 30-
day mortality ranges between 2%-3% for lobectomy and 3%-8% for pneumonectomy 
76, 77. Importantly, it has been recognised that there is a significant relationship 
between volume and outcome in surgery of lung cancer, supporting the notion that 
these procedures should be restricted to experienced centres 77.  
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8. Do patient characteristics contribute to treatment 
decisions in stage III NSCLC? 
 
8.1. Age 
 
Age itself has not been shown to influence outcome following surgery plus 
adjuvant chemotherapy or definitive concurrent chemoradiotherapy [I, A]. 
However, data are limited for the elderly population and, in particular, in 
patients above 75 years of age. 
 
Age alone is not a good parameter to predict outcome in stage III disease after 
surgery and adjuvant chemotherapy. Due to the small numbers, an exploratory 
analysis of the randomised trial from the National Cancer Institute of Canada in 
patients over 80 years failed to demonstrate a benefit of adjuvant chemotherapy 
104. On the other hand, the LACE meta-analysis did not show a negative impact of 
age on the outcome of adjuvant chemotherapy 7. Furthermore, the outcome of 
elderly patients was not inferior in the chemoradiotherapy trials by the Cancer and 
Leukemia Group B and the RTOG 23. A recent analysis of data from the SEER 
database showed that treatment of elderly patients with stage IIIA (N2) NSCLC is 
highly variable in North America and varies not only with specific patient and tumour 
characteristics but also with regional income level 105]. However, the number of 
elderly patients in all randomised adjuvant and chemoradiotherapy trials is still too 
small to allow for robust conclusions. Until more evidence is generated, comorbidity 
issues should predominate over age alone with respect to decision-making. 
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8.2. Performance status (PS) 
 
Reduced PS is a significant negative prognostic factor with regard to OS 
results following a treatment strategy of surgery plus adjuvant therapy. 
Treatment planning must be therefore be individualised [III, B]. 
 
While data on age are still controversial, increasingly PS is accepted as a significant 
negative prognostic factor in stage III disease. This has been demonstrated in the 
context of patients treated by surgery plus adjuvant chemotherapy and also in 
definitive chemoradiotherapy protocols 7, 25, 99. When treatment decisions are to 
be made for patients with PS Eastern Cooperative Oncology Group 2, an individual 
risk/benefit analysis is particularly important. Medical history (e.g. infections) resulting 
in reduced PS should be analysed, and every attempt to treat a reversible condition 
and, thereafter, potentially improve the general condition and PS must be 
considered. 
 
9. Is there a place for targeted agents in the treatment of 
stage III NSCLC? 
 
There is currently no role for targeted agents in stage III NSCLC outside clinical 
trials [I, A].  
 
The large randomised SWOG trial in North America demonstrated an inferior OS in a 
patient group receiving an epidermal growth factor receptor (EGFR) tyrosine kinase 
inhibitor (gefitinib) as consolidation therapy compared with placebo after 
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chemoradiotherapy and consolidation docetaxel 106. The reasons for this 
detrimental effect are still to be explored, looking at potential specific toxicities 
following chemoradiotherapy and/or docetaxel or underlying tumour-related adaptive 
biological mechanisms. Gefitinib was also evaluated as adjuvant treatment in the 
postoperative setting for stage IB-II-IIIA disease patients in a phase III underpowered 
trial, with disappointing results 107. However, this study did not select the recruited 
patient population on the basis of EGFR mutations. Therefore, any interpretation for 
the subset of EGFR mutated patients should be considered with caution. A third 
randomised trial has recently been presented – the North American four-arm 
randomised trial using cetuximab in addition to concurrent chemoradiotherapy that 
was also unable to demonstrate any benefit from the addition of the targeted agent 
82. Outside well-designed and closely monitored clinical trials in target-based 
selected populations, there is currently no role for targeted agents in stage III 
NSCLC. 
 
10. What is the optimum follow-up after radical therapy for 
stage III NSCLC patients? 
 
10.1. After radical therapy 
 
Thoracic and upper abdominal CT scan (including adrenals) should be 
performed every 6 months for 2 years, and yearly thereafter [III, C] for 3 years. 
No routine PET-CT is recommended. It might be considered only in the case of 
abnormalities detected by CT scan [III, C]. 
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No evidence from randomised trials is available to define optimal follow-up in treated 
stage III NSCLC patients. PET-CT – although of considerable value in initial staging 
for stage III disease patients – has no routine role for the follow-up of stage III 
NSCLC patients after surgical-based multimodality treatment 108. A large French 
randomised trial has been performed to investigate follow-up in surgically 
(completely) resected patients with stage I to III and results are awaited 109. 
Currently, experts can only extrapolate recommendations for follow-up strategies, 
either based on evidence from follow-up policies in large published clinical trials, 
individual physician choices or on consented local (“Cancer Centre”) policies. In 
selected cases, ambiguous abnormalities detected on CT scans may be individually 
further investigated with PET-CT follow-up, but final cytological or histological 
confirmation (e.g. bronchoscopy, EBUS/EUS) is usually recommended to confirm a 
suspicion of relapse. 
 
 
10.2. Brain imaging methods 
 
Patients with stage III disease following multimodality treatment have a high 
risk of brain relapse. Selected patients with a high risk of brain relapse may be 
followed-up with brain imaging methods aiming at early detection and 
treatment of single site relapses with curative intent [V, C]. 
 
Long-term survival patterns in stage III NSCLC trials have pointed to the very high 
cumulative risk of developing brain metastases after multimodality treatment 41, 42. 
Adenocarcinoma patients, in particular, may represent a specific subgroup with an 
increased risk profile. Availability of modern radiation techniques for oligometastatic 
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brain lesions in recent years (e.g. stereotactic brain radiotherapy) may argue in 
favour of an individualised follow-up using brain MRI to detect these oligometastatic 
brain failures, which are now amenable to local treatment.  
 
10.4. Smoking cessation 
 
Patients treated for stage III disease should be strongly encouraged to quit 
smoking and/or participate in smoking cessation programmes [I, A]. 
 
Long-term survival analysis, relapse patterns and competing risk analysis of stage III 
NSCLC patients including the risk of developing second lung cancers and smoking-
related events (comorbidity events) are strong arguments to implement smoking 
cessation programmes as part of any curatively intended management of early and 
locally advanced NSCLC patients including stage III disease 65, 110, 111. 
 
note 
Levels of evidence and grades of recommendation have been applied using the 
system shown in Table 1. Statements without grading were considered justified 
standard clinical practice by the experts and the ESMO faculty. 
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Legends: 
 
Table 1. Levels of evidence and grades of recommendation (adapted from the 
Infectious Diseases Society of America-United States Public Health Service Grading 
Systema) 
 
Table 2. Patient subsets and substages included into stage III non-small-cell lung 
cancer 
 
Figure 1. Suggested algorithm for treatment in patients with logoregional non-small-
cell lung cancer, based on imaging, invasive lymph node staging tests and 
multidisciplinary assessment. Reproduced from [16]. By permission of Oxford 
University Press, on behalf of ESMO. 
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 Levels of evidence 
I Evidence from at least one large randomised, controlled trial of good 
methodological quality (low potential for bias) or meta-analyses of well-
conducted randomised trials without heterogeneity 
II Small randomised trials or large randomised trials with a suspicion of bias 
(lower methodological quality) or meta-analyses of such trials or of trials 
with demonstrated heterogeneity 
III Prospective cohort studies 
IV 
 
Retrospective cohort studies or case–control studies  
 
V Studies without control group, case reports, experts opinions 
 
Grades of recommendation 
A Strong evidence for efficacy with a substantial clinical benefit, strongly 
recommended 
B Strong or moderate evidence for efficacy but with a limited clinical benefit, 
generally recommended 
C Insufficient evidence for efficacy or benefit does not outweigh the risk or the 
disadvantages (adverse events, costs, ...), optional  
D              Moderate evidence against efficacy or for adverse outcome, generally not 
recommended 
E              Strong evidence against efficacy or for adverse outcome, never recommended 
 
aDykewicz CA. Summary of the guidelines for preventing opportunistic infections 
among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139–
144. By permission of the Infectious Diseases Society of America. 
 
 
 IASLC/UICC 7 Definition TNM subsets Description Robinson Classification 
IIIA incidental N2 
(unforeseen N2) 
T1-3 N2 N2 found at surgery 
microscopic N2 
macroscopic N2 
 
IIIA1 
IIIA2 
IIIA potentially resectable N2 T1-3 N2 minimal N2/single station at staging IIIA3 
IIIA potentially resectable N2 
But: risk of incomplete resection 
T1-3 N2 Pancoast tumour subsets, T3-4 N1, T3 
N2 selective centrally located IIIA(N2) 
------ 
IIIA3 
IIIA unresectable N2 T1-3 N2 bulky and/or multilevel N2 at staging IIIA4 
IIIA potentially resectable T4 
But: risk of incomplete resection 
T4 N0-1 pulmonary artery, carina, spine, 
trachea, vena cava, right atrium 
------ 
IIIB unresectable T4 T4 N0-1 
T4 N2 
oesophagus, heart, aorta, pulmonary 
veins 
------ 
IIIB unresectable N3 T1-4 N3 N3 nodes at staging  
 
 
